Crescent Biopharma reports news about its clinical-stage oncology pipeline, including CR-001, a PD-1 x VEGF bispecific antibody, and antibody-drug conjugate programs such as CR-002 and CR-003. Company updates commonly cover clinical trial activity in solid tumors, pipeline combinations, collaboration activity, financial results, and business highlights.
Recurring corporate announcements also include investor conference presentations and equity inducement awards under the company’s employment inducement incentive plan. These updates reflect Crescent’s status as a Nasdaq-listed biotechnology issuer focused on cancer therapeutics.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced that CEO Rachel King will present at the Stifel 2020 Virtual Healthcare Conference on November 17 and the Jefferies Virtual London Healthcare Conference on November 19. The presentations can be accessed on the company's website under the Investors tab. GlycoMimetics is focused on innovative glycomimetic drugs for unmet medical needs, including treatments for acute myeloid leukemia and sickle cell disease. Uproleselan is in a Phase 3 trial for relapsed/refractory AML, and Rivipansel is investigating acute VOC in SCD.
GlycoMimetics, Inc. (Nasdaq: GLYC) reported Q3 2020 financial results, highlighting cash and equivalents of $142.9 million. The Phase 3 trials for uproleselan in AML are progressing, with enrollment completion projected in H2 2021. Significant data from rivipansel's Phase 3 RESET trial indicates improved discharge times in early crisis treatment. General and administrative expenses rose to $4.1 million, while R&D expenses remained stable at $10.7 million for Q3. CEO Rachel King emphasized the company's commitment to advancing its pipeline amidst the ongoing pandemic.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced that five abstracts from its clinical portfolio have been accepted for presentations at the 62nd ASH Annual Meeting, scheduled for December 5-8, 2020. Key highlights include positive findings from the Phase 3 RESET study of rivipansel, indicating shorter hospital stays and reduced opioid use for sickle cell disease patients. Additionally, GMI-1687's potential for intravenous and subcutaneous administration was presented, alongside data on uproleselan's efficacy in acute myeloid leukemia (AML). These presentations suggest novel treatment pathways for unmet medical needs.
GlycoMimetics, Inc. (Nasdaq: GLYC) is set to host a conference call on November 6, 2020, at 8:30 a.m. ET to discuss its third quarter financial results. The call can be accessed domestically at (844) 413-7154 or internationally at (216) 562-0466, with a participant code of 3073766. The company is focused on developing glycomimetic drugs for unmet medical needs, with late-stage programs including uproleselan, currently in a Phase 3 trial for AML, and rivipansel for SCD. A webcast replay of the call will be available for 30 days on their website.
GlycoMimetics, Inc. (Nasdaq: GLYC) has announced new data from post hoc analyses of the Phase 3 RESET study, indicating that pediatric patients treated with rivipansel within 30 hours of pain onset showed significant improvements in discharge readiness and reduced IV opioid use compared to placebo. Key metrics include a median time to readiness for discharge reduced by 29.3 hours and time to discharge reduced by 23.2 hours. Additionally, rivipansel demonstrated a favorable safety profile, prompting GlycoMimetics to engage with the FDA regarding future steps in its development for acute vaso-occlusive crises (VOC).
GlycoMimetics, Inc. (Nasdaq: GLYC) has received Rare Pediatric Disease designation from the FDA for rivipansel, aimed at treating sickle cell disease in patients 18 and younger. This recognition underlines the urgent need for effective treatments for pediatric patients suffering from this serious condition. GlycoMimetics holds global rights for rivipansel and is in discussions with the FDA regarding regulatory pathways for approval. The company also plans to present comprehensive data from its Phase 3 RESET program at upcoming medical meetings.